NASDAQ:ZIOP - ZIOPHARM Oncology Stock Price, Forecast & News

ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) posted its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.34. View ZIOPHARM Oncology's Earnings History.

ZIOPHARM Oncology is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for ZIOPHARM Oncology.

4 Wall Street analysts have issued 12-month price objectives for ZIOPHARM Oncology's stock. Their forecasts range from $6.50 to $7.50. On average, they expect ZIOPHARM Oncology's stock price to reach $6.88 in the next twelve months. This suggests a possible upside of 116.2% from the stock's current price. View Analyst Price Targets for ZIOPHARM Oncology.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZIOPHARM Oncology in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ZIOPHARM Oncology.

News stories about ZIOP stock have trended extremely negative on Tuesday, according to InfoTrie. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ZIOPHARM Oncology earned a coverage optimism score of -5.0 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for ZIOPHARM Oncology.

Some companies that are related to ZIOPHARM Oncology include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other ZIOPHARM Oncology investors own include Intrexon (XON), Celgene (CELG), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), Amarin (AMRN), Immunomedics (IMMU), Inovio Pharmaceuticals (INO), Opko Health (OPK), Arena Pharmaceuticals (ARNA) and Sarepta Therapeutics (SRPT).

ZIOPHARM Oncology's stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (3.28%), Charles Schwab Investment Management Inc. (0.55%), UBS Group AG (0.38%), Bank of New York Mellon Corp (0.38%), California Public Employees Retirement System (0.20%) and Vident Investment Advisory LLC (0.17%). Company insiders that own ZIOPHARM Oncology stock include David M Md Mauney, Groot Eleanor De, Kevin G Lafond, Laurence James Neil Cooper and Robert Hadfield. View Institutional Ownership Trends for ZIOPHARM Oncology.

ZIOP stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, UBS Group AG, Rafferty Asset Management LLC, Renaissance Technologies LLC, Goldman Sachs Group Inc., Bank of America Corp DE, Creative Planning and New York State Common Retirement Fund. Company insiders that have sold ZIOPHARM Oncology company stock in the last year include David M Md Mauney, Groot Eleanor De, Kevin G Lafond, Laurence James Neil Cooper and Robert Hadfield. View Insider Buying and Selling for ZIOPHARM Oncology.

ZIOP stock was bought by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, First Trust Advisors LP, California Public Employees Retirement System, UBS Asset Management Americas Inc., Bank of New York Mellon Corp, Vident Investment Advisory LLC, Virtus ETF Advisers LLC and Banque Cantonale Vaudoise. View Insider Buying and Selling for ZIOPHARM Oncology.

Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ZIOP stock can currently be purchased for approximately $3.18.

ZIOPHARM Oncology has a market capitalization of $575.68 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-53,120,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. ZIOPHARM Oncology employs 48 workers across the globe.View Additional Information About ZIOPHARM Oncology.

The official website for ZIOPHARM Oncology is http://www.ziopharm.com/.

ZIOPHARM Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. The biotechnology company can be reached via phone at 617-259-1970 or via email at [email protected]